[Hot Stock] LaserOptek Surges on News of World’s First Triple-Wavelength Laser System FDA Approval

LaserOptek is showing strong performance. This is attributed to the news that its laser device for pigment disease treatment, 'Helios 785,' has obtained premarket approval (510k) from the U.S. Food and Drug Administration (FDA).

As of 9:30 AM on the 11th, LaserOptek is trading at 7,870 KRW, up 22.97% compared to the previous day.

The FDA's 510(k) is an approval system that verifies the safety and effectiveness of a medical device by comparing it to an existing certified product before market release.

LaserOptek's Helios series is a device used for treating various pigment disorders including melasma, whitening, removal of various color tattoos, toning, and is supplied to over 40 countries worldwide.

The latest product in the Helios series, the Helios 785 laser, features triple wavelengths of 785/1064/532nm and integrates pico and nano lasers on one platform. It is known to minimize side effects and provide safe treatment tailored to various skin types, specializing in pigment treatment.

This content was produced with the assistance of AI translation services.